AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
- Recruiting participants (Starts May. 1, 2015)
- Not accepting healthy volunteers
- UTSW Principal Investigator: Martha Marie Pacheco
summary
See protocol/CiRB application
eligibility
See protocol/CIRB Application